2017 ESC Guidelines for themanagement of acutemyocardial infarction

in patients presenting with ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Agewall Stefan
Antunes Manuel J
Bucciarelli-Ducci Chiara
Bueno Hector
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Thermo Fischer Scientific : Cardiac markers (2015)
- Vifor International : Heart failure (2015)
- Astra Zeneca : Platelet inhibition (2015)
- Astra Zeneca : Antiplatelet treatment (2016)
Nothing to be declared (2015-2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Circle Cardiovascular Imaging, Inc : Imaging software (2015)
- Circle Cardiovascular Imaging, Inc : Software for cardiac MRI imaging analysis (2016)
D - Research funding (departmental or institutional).
- National Institute of Health Research (NIHR) - United Kingdom : Health research (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer Healthcare : Aspirin (2015)
- Sanofi Aventis : Clopidogrel (2015)
- Daiichi Sankyo : Prasugrel (2015)
- Eli Lilly : Prasugrel (2015)
- Novartis : Serelaxin, LCZ696 (2015)
- Pfizer : Apixaban (2015-2016)
- Bristol Myers Squibb : Apixaban (2015-2016)
- Servier : ivabradine (2015-2016)
- Astra Zeneca : Ticagrelor (2015-2016)
- Ferrer Internacional : Trinomia (polypill) (2015-2016)
- Bayer : Aspirin, rivaroxaban (2016)
- Abbott : BVS (2016)

23/08/2017 1/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Bueno Hector - MEDSCAPE-the heart.og : Inespecific (2016)

Caforio Alida L P
Crea Filippo
Goudevenos John A
- Novartis : Serelaxin, ACZ885, AHF Academy (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Ticagrelor (2015-2016)
E - Research funding (personal).
- Astra Zeneca : Ticagrelor (2015)
- BMS : CV013-011 - STANDUP-AHF trial (2016)
- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)
- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016)
- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Menarini : heart failure, speaker fees (2015-2016)
- Genzyme : rare cardiac disease, Fabry disease, speaker fees (2015-2016)
- Shire HGT : rare cardiac disease, Fabry disease, speaker fees, consultant fees (2015-2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Advisory Board (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : Phd Research Founding (2016)
- Biotronik : Phd Research Founding (2016)
C - Receipt of royalties for intellectual property.
- Edizioni Edra : Rugarli - Medicina Interna Sistematica (2015)
- Springer : Coronary microvascular dysfunction (2015-2016)
D - Research funding (departmental or institutional).
- Boehringer-Ingelheim : PHD Research funding (2015)
- Biotronik : PHD Research funding (2015)
Nothing to be declared (2015-2016)

23/08/2017 2/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Halvorsen Sigrun
Hindricks Gerhard
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bristol Myers Squibb : Antithrombotic treatment (2015-2016)
- Astra Zeneca : Anti-thrombotic treatment (2015-2016)
- Boehringer-Ingelheim : Anti-thrombotic treatment (2015-2016)
- Pfizer : Anti-thrombotic treatment (2015-2016)
- Bayer AS : Anti-thrombotic treatment (2015-2016)
- Sanofi Aventis : Cholesterol lowering treatment (2015-2016)
- Merck Sharp & Dohme : Cholesterol lowering treatment (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Sharp & Dohme : Lipid-lowering treatment (2015)
- Boehringer-Ingelheim : Anti-thrombotic treatment (2015-2016)
- Sanofi Aventis : Lipid lowering treatment (2015-2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : IC, CRT, Catheter Ablation (2015)
- Biotronik : ICD CRT (2015)
- St Jude Medical : ICD, CRT, Catheter Ablation (2015)
- Boston Scientific : CIEDs and interventional electrophysiology (2016)
- St Jude Medical : CIEDs and interventional electrophysiology (2016)
- Biotronik : CIEDs and interventional electrophysiology (2016)
D - Research funding (departmental or institutional).
- Daiichi Sankyo : atrial fibrillation, anticoagulation (2015)
- Boston Scientific : ICD, CRT, Catheter Ablation (2015)
- St Jude Medical : ICD, CRT, Catheter Ablation (2015)
- Biotronik : ICD, CRT, Catheter Ablation (2015)

23/08/2017 3/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Hindricks Gerhard - Zoll Medical : wearable ICD (2015)

- Boston Scientific : CIEDs and interventional electrophysiology (2016)
- St Jude Medical : CIEDs and interventional electrophysiology (2016)
Ibanez Borja D - Research funding (departmental or institutional).
- Astra Zeneca : I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO drugs
or products involved. (2015-2016)
James Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer : Anti coagulation (2016)
- Boston Scientific : Stents (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer : anti coagulation (2015)
- Astra Zeneca : platelet inhibition (2015)
- Medicines Company : Anti thrombotics (2016)
- Astra Zeneca : Antiplatelet (2016)
- Abbott : Stents (2016)
- Boston Scientific : stents (2016)
D - Research funding (departmental or institutional).
- The Medicines Company : anti coagulation (2015)
- Astra Zeneca : Anti platelet (2015)
- Abbot Vascular : stents (2015)
- Astra Zeneca : Anti thrombotics (2016)
Kastrati Adnan Nothing to be declared (2015-2016)
Lenzen Mattie Nothing to be declared (2015-2016)
Prescott Eva Nothing to be declared (2015)

23/08/2017 4/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Prescott Eva B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astrazeneca : Microvascular disease (2016)
Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Johnson & Johnson : coronary catheters (2015-2016)
- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)
- Terumo Inc : coronary catheters (2016)
D - Research funding (departmental or institutional).
- Biosensors : devices (2015)
- Boston Scientific : devices (2015-2016)
- Medtronic : devices (2015-2016)
- Biotronik : devices (2015-2016)
- Terumo Inc : devices (2015-2016)
- Abbott Vascular : devices (2015-2016)
Valgimigli Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : Oral anticoagulation (2015)
- Astra Zeneca : Antiplatelet agents (2016)
- Terumo Inc : Coronary stent (2016)
- Abbott Vascular : Coronary Stent (2016)
- Sinomed : Coronary stent (2016)
- Bayer : Oral anticoagulation (2016)
- Correvio : Tirofiban (2016)
D - Research funding (departmental or institutional).
- Astra Zeneca : Anti platelet agents (2016)
- Medicure : Antiplatelet agents (2016)
- Terumo Inc : Coronary stent (2016)

23/08/2017 5/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Valgimigli Marco - The Medicines Company : parenteral anticoagulation (2016)

Varenhorst Christoph
Vranckx Pascal
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : apixaban (2015)
- Bristol Myers Squibb : apixaban (2015)
- CSL Behring : bleeding disorder therapies (2015)
- Boehringer-Ingelheim : dabigatran (2015)
- Astra Zeneca : ticagrelor (2015)
- Astra Zeneca : Acute Coronary Syndromes (2016)
- Boehringer-Ingelheim : Antithrombotics (2016)
- Pfizer : Antithrombotics (2016)
- Bristol Myers Squibb : Antithrombotics (2016)
- Bayer AG : Antithrombotics (2016)
- CSL Behring : Haemostasis (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : ticagrelor (2015)
- Astra Zeneca : Acute Coronary Syndromes (2016)
D - Research funding (departmental or institutional).
- Medicines Company : bivalirudin (2015)
- Astra Zeneca : ticagrelor, antidiabetics (2015)
- Medicines Company : Antithrombotics (2016)
- Astra Zeneca : RWE research (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer Healthcare : coagulation (2015)
- Astra Zeneca : P2Y12 inhibition (2015)

23/08/2017 6/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Task Force
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Vranckx Pascal - Daiichi Sankyo : NOAC (2015-2016)

- Bayer Healthcare : NOAC (2015-2016)
Widimsky Petr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : Antithrombotic agents (2015)
- Eli Lilly : Antithrombotic agents (2015)
- Abbott : Stents (2015)
- Servier : Antiischemic agents (2015-2016)
- Astra Zeneca : Antithrombotic agents (2015-2016)
- Bayer : Antithrombotic agents (2015-2016)
- Boehringer-Ingelheim : Antithrombotic agents (2015-2016)
- Medtronic : Stents (2015-2016)

23/08/2017 7/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Aboyans Victor
Aladashvili Alexander
Antoniades Loizos
Bajraktari Gani
Baumbach Andreas
Beauloye Christophe
Beishenkulov Medet
Benlamin Hisham
23/08/2017
2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
Type of Relationship with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Amgen : Hyperlipidemia (2016)
- Novartis : Hypertension (2016)
- Boehringer-Ingelheim : Oral anticoagulation (2016)
- Bayer Healthcare : Oral anticoagulation (2016)
- Pfizer/BMS alliance : Oral anticoagulation (2016)
Nothing to be declared (2016)
Nothing to be declared (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Drugs (2016)
- Keystone Heart : EMbolic Protection (2016)
- Abiomed : LV Assist (2016)
- Abbott Vascular : Stents (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott Vascular : Stents (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Speaker Fees (2016)
D - Research funding (departmental or institutional).
- Astra Zeneca : Research Grant (2016)
- Bayer : Research Grant (2016)
- Medtronic : Research Grant (2016)
- Pfizer : Research Grant (2016)
Nothing to be declared (2016)
Nothing to be declared (2016)
8/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Berkinbayev Salim
Bertelli Luca
Bolognese Leonardo
Bugiardini Raffaele
Bunc Matjaz
Chettibi Mohamed
Collet Jean-Philippe
23/08/2017
2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
Type of Relationship with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier : Cardiology (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra : antiplatelet therapy, antianginal Rx, stents (2016)
D - Research funding (departmental or institutional).
- Astra Zeneca : antiplatelet therapy (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Edwards Lifesciences : TAVI, proctor (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Medtronic : TAVI, proctor (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- BMS : apixaban (2016)
- Sanofi Aventis : CLOPIDOGREL (2016)
- Medtronic : corevalve (2016)
- Eli Lilly : PRASUGREL (2016)
- Astra-Zeneca : ticagrelor (2016)
- MSD : VORAPAXAR (2016)
- Bayer Healthcare : xarelto (2016)
D - Research funding (departmental or institutional).
- Bristol Myers Squibb : APIXABAN (2016)
- Medtronic : COREVALVE (2016)
- Stago : LABORATORY TEST (2016)
- Eli Lilly : PRASUGREL (2016)
9/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Collet Jean-Philippe - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

Coman Ioan Mircea
- ICAN : THROMBOSIS (2016)
- Astra Zeneca : TICAGRELOR (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : anticoagulants (2016)
- Johnson & Johnson : antithrombotic (2016)
- Bayer AG : antithrombotic (2016)
- Sanofi Aventis : dyslipidemia (2016)
- Fournier Laboratories : dyslipidemia (2016)
- Amgen Inc : dyslipidemia , (2016)
- Novartis : HF (2016)
- Vifor International : iron deficiency (2016)
- Actelion : PHT (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : anticoagulants (2016)
- Johnson & Johnson : antithrombotic (2016)
- Bayer AG : antithrombotic (2016)
- Sanofi Aventis : dyslipidemia (2016)
- Amgen Inc : dyslipidemia (2016)
- Fournier Laboratories : dyslipidemia (2016)
- Novartis : HF (2016)
- Vifor International : iron deficiency (2016)
- Actelion : PHT (2016)

23/08/2017 10/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Delgado Victoria
Dizdarevic-Hudic Larisa
Elsaesser Albrecht
23/08/2017
2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
Type of Relationship with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott Vascular : Mitraclip (2016)
D - Research funding (departmental or institutional).
- Boston Scientific : Pacemaker-Heart failure (2016)
- Medtronic : Pacemaker-Heart failure (2016)
- Biotronik : Pacemaker-Heart Failure (2016)
- Edwards Lifesciences : Valvular heart disease (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : Ertugliflozin (subinvestigator in study) (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : ACS (2016)
- Edwards Lifesciences : Aortic Valve (2016)
- Daiichi Sankyo : Complications PCI (2016)
- Novartis : Heart failure (2016)
- St Jude Medical : OCT, PCI (2016)
- Abbott Vascular : Scaffold (2016)
- Elixir : Scaffold (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : ACS (2016)
- Edwards Lifesciences : Aortic Valve (2016)
- Daiichi Sankyo : Complications PCI (2016)
- Novartis : Heart failure (2016)
- St Jude Medical : OCT, PCI (2016)
- Abbott Vascular : Scaffold (2016)
- Elixir : Scaffold (2016)
11/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Fitzsimons Donna Nothing to be declared (2016)

Gaemperli Oliver
Gale Christopher Peter
Garcia de Castro Ana Maria Nothing to be declared (2016)
Gershlick Tony
Gielen Stephan
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- GE-Healthcare : Imaging (2016)
- Amgen Inc : PCSK9 (2016)
- Servier : Procorolan (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astrazeneca : ACS, heart failure (2016)
- Novartis : heart failure (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott Vascular : BAS (2016)
- Medicines Company : cangrelor/ bivalirudin (2016)
- Medtronic : DES (2016)
- Astra Zeneca : Ticagrelor (2016)
D - Research funding (departmental or institutional).
- Abbott Vascular : BAS (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Lectures, Advisory Board (2016)
- Elixir : travel support (2016)
- Sanofi Aventis : travel support ESC Congress (2016)
- Novartis : Travel support for the German Cardiac Society meeting 2016, honorarium for lectures (2016)
- Amgen Inc : Travel support for the German Cardiac Society meeting 2017, honorarium for lectures/advisory board (2016)
- Biosensors : Travel support German Cardiac Society meeting 2015 (2016)
C - Receipt of royalties for intellectual property.
- Oxford University Press : Editor, Preventive Cardiology Textbook (2016)

23/08/2017 12/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Gilard Martine
Gudnason Thorarinn
Gustiene Olivija
Harjola Veli-Pekka
23/08/2017
2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
Type of Relationship with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer Healthcare : medication (2016)
- Medtronic : TAVI (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : medication (2016)
- Terumo Inc : OCT/stent (2016)
- Abbott Vascular : Stent (2016)
- Edwards Lifesciences : TAVI (2016)
- GE Healthcare : Technology (2016)
Nothing to be declared (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antiplatelet, ticagrelor (2016)
- Krka Pharma : Atorvastatin (2016)
- Berlin Menarini : Hypertension, infarction, Zofenopril (2016)
- Servier : Stable angina, ivabradin (2016)
D - Research funding (departmental or institutional).
- Amgen : Amgen, Principal Investigator,Start of End of Study Visit Period: 2-Sept-16, The EOS Visit period will complete on
11-Nov-16 (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Roche Diagnostics : Cardiac markers (2016)
- Novartis : Heart failure (2016)
- Orion : Heart failure (2016)
- Pfizer : Venous thromboembolism (2016)
- Merck Sharp & Dohme : Venous thromboembolism (2016)
- Bayer AG : Venous thromboembolism (2016)
13/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Hayrapetyan Hamlet
Iakobishvili Zaza
Ibrahimov Firdovsi
Jeger Raban
Juliebo Vibeke
Kanakakis Ioannis-
Georgios
Karamfiloff Kiril
Katus Hugo
Kedev Sasko
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier : Arterial Hypertension (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim, Novartis : Dabigatran, Sacubitril/valsartan (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- B.Braun : DCB (Sequent Please) (2016)
- St Jude Medical : TAVI (Portico) (2016)
D - Research funding (departmental or institutional).
- B.Braun : BASKET-SMALL 2 (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : ANTIPLATELETS (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- GlaxoSmithKline : ACS ,INFLAMMATION (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : Lixiana_NOAK (2016)
- Astra Zeneca : Ticagrelor (2016)
- Bayer Vital : Xarelto-NOAK (2016)
D - Research funding (departmental or institutional).
- St Jude Medical : Biobank (2016)
- Philips : MRT (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : Speaker fees (2016)
- Medtronic : Speaker fees (2016)
- Terumo Inc : Speaker fees (2016)

23/08/2017 14/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Kedev Sasko - Meril : Speaker fees (2016)

Knuuti Juhani
Kolh Philippe H
Kristensen Steen Dalby
Leclercq Christophe
Legutko Jacek
D - Research funding (departmental or institutional).
- Orion : Brain diseases (2016)
- AC Immune : Brain diseses (2016)
- Antaros : Endocrinology (2016)
- Boehringer-Ingelheim : Neurology (2016)
- MSD : Neurology (2016)
- GE Gealthcare : Neurology (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antiplatelet agents (2016)
- B.Braun : Surgical instruments (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Aspen : anti-thrombotics fondaparinux (2016)
- Bayer AG : anti-thrombotics rivaroxiban (2016)
- Astra Zeneca : anti-thrombotics Ticagrelor (2016)
D - Research funding (departmental or institutional).
- Astra Zeneca : ticagrelor (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : devices (2016)
- Medtronic : devices (2016)
- Sorin Group : devices (2016)
- St Jude Medical : devices (2016)
- Biotronik : devices (2016)
- Bayer Healthcare : DOAC (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bracco Pharmaceutical : Interventional cardiology (IVUS, FFR) (2016)

23/08/2017 15/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Legutko Jacek - Volcano : Interventional cardiology (IVUS, FFR) (2016)

- Abbott : Interventional cardiology (stents, balloons, wires, MitraClip, etc.) (2016)
- Balton : Interventional cardiology (stents, balloons, wires, valves etc.) (2016)
- Terumo Inc : Interventional cardiology (stents, balloons, wires, valves, OFDI, etc.) (2016)
- Medtronic : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) (2016)
- Merck Sharp & Dohme : Simvastatin, ezetimib, etc. (2016)
- Astra Zeneca : Tikagrelor (2016)
Lip Gregory Y H B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Medtronic : AF screening (2016)
- BMS/Pfizer : Anticoagulation (2016)
- Boehringer Ingelheim : Anticoagulation (2016)
- Bayer/Janssen : Anticoagulation (2016)
- Daiichi-Sankyo : Daiichi-Sankyo (2016)
D - Research funding (departmental or institutional).
- BMS/Pfizer : AF Registries [unrestricted educational grant] (2016)
- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Marandi Toomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antithrombotics (2016)
Merkely Bela A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Sanofi Aventis : ACS (2016)
- Medtronic : CRT course (2016)
- Abbott : CRT/ICD (2016)
- Servier : Heart Failure (2016)
- Biotronik : ICD/CRT (2016)

23/08/2017 16/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Merkely Bela
Metzler Bernhard
Morais Joao
Mourali Mohamed Sami
Nedeljkovic Milan
Neskovic Aleksandar N
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott : cardiac rhythm management (2016)
- Medtronic : cardiac rhythm management (2016)
- Boston Scientific : CRT (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : Anticoagulants (2016)
- Bayer Healthcare : Anticoagulants (2016)
- Bristol Myers Squibb : Anticoagulants (2016)
- Boehringer Ingelheim : Anticoagulants (2016)
- Astra Zeneca : Antiplatelets (2016)
- Merck Sharp & Dohme : Antiplatelets, lipids (2016)
- Boston Scientific : Left Atrial Apendage Closure (2016)
- Amgem : Lipids (2016)
Nothing to be declared (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Medtronic : advisory board fees (2016)
- Bayer Healthcare : honoraria, consultancy (2016)
- Servier : speaker fees (2016)
- PharmaSwiss : speaker fees (2016)
- Astra Zeneca : speaker fees, advisory board fees, consultancy (2016)
E - Research funding (personal).
- Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-
2015 (2016)

23/08/2017 17/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Neumann Franz Josef
Niemela Matti
Niessner Alexander
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : Anticoagulant Therapy (2016)
- Daiichi Sankyo : Anticoagulant therapy (2016)
- Pfizer : Anticoagulant therapy (2016)
- Bayer Healthcare : Anticoagulant therapy (2016)
- Bristol Myers Squibb : Anticoagulant therapy (2016)
- Astra Zeneca : Antiplatelet therapy (2016)
- Boston Scientific : Interventional cardiology (2016)
- Edwards Lifesciences : Transcatheter valves (2016)
- Medtronic : Transcatheter valves (2016)
D - Research funding (departmental or institutional).
- Bayer Healthcare : Anticoagulant therapy (2016)
- Novartis : Heart failure (2016)
- Pfizer : Heart failure (2016)
- GlaxoSmithKline : Heart failure (2016)
- Biotronik : Interventional Cardiology (2016)
- Abbott Vascular : MitraClip (2016)
- Edwards Lifesciences : Transcatheter Valves (2016)
- Medtronic : Transcatheter Valves (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer : anticoagulation (2016)
- Daiichi Sankyo : anticoagulation (2016)
- Pfizer : anticoagulation (2016)

23/08/2017 18/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Niessner Alexander - Bristol Myers Squibb : anticoagulation (2016)

Parkhomenko Alexander
Pereira Bruno
Petursson Petur
Piepoli Massimo Francesco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : anticoagulation, antidiabetic therapy (2016)
- Novo-Nordisk : antidiabetic therapy (2016)
- Astra Zeneca : antitthrombotic therapy (2016)
- St Jude Medical : interventional cardiology (2016)
D - Research funding (departmental or institutional).
- Boehringer-Ingelheim : atrial fibrillation (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- BHFZ : corvitin (2016)
- Sanofi Aventis : enoxaparin (2016)
- Servier : preductal (2016)
- Bayer Healthcare : rivaroxaban (2016)
- Astra Zeneca : ticagrelor (2016)
D - Research funding (departmental or institutional).
- European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Speaker Fee (2016)
- Menarini : Speaker Fees (2016)
- Merck Sharp & Dohme : Speaker Fees (2016)
Nothing to be declared (2016)
- Servier : Committee member, Speaker fee (2016)
- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)
- Amgen : Metabolic, Lipid (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis : Heart Failure Prevention Initiatives (2016)

23/08/2017 19/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Richter Dimitrios
Shaheen Sameh Mohamad A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Menarini : CAD- hypertension (2016)
- Novartis : hypertension (2016)
- Abbott : lipids (2016)
- Amgen : lipids (2016)
- Sanofi Aventis : Lipids (2016)
- Lilly : Lipids (2016)
- Unilever : lipids (2016)
- Merck Sharp & Dohme : lipids (2016)
- Angelini : Lipids (2016)
- Vianex : lipids (2016)
- Galenica : Lipids (2016)
- Teva Pharmaceutical Industries : lipids, hypertension (2016)
- Swisspharma : lipids-hypertension (2016)
- Astra Zeneca : lipids-thrombosis (2016)
- Pfizer : lipids-thrombosis (2016)
- Winmedica : lipids-thrombosis (2016)
- Boehringer-Ingelheim : thrombosis (2016)
- Bayer Healthcare : Thrombosis (2016)
- Novartis : Antihypertensives (2016)
- Astra Zeneca : Antiplatelets (2016)
- Pfizer : NOACS (2016)

23/08/2017 20/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Shlyakhto Evgeny
Simpson Iain A
Skoric Bosko
Steg Philippe Gabriel
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Krka Pharma : Arterial Hypertension (2016)
- Novartis : Arterial Hypertension, Heart Failure (2016)
- Merck Sharp & Dohme : Atherosclerosis (2016)
- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016)
- Pfizer : General Cardiology (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Teva Pharmaceutical Industries Pliva : Diuron (2016)
- Mylan : Dualtis (2016)
- Novartis : Exforge HCT (2016)
- Boehringer-Ingelheim : Jardiance (2016)
- Berlin Chemie AG : Zofecard (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier : antianginal agents (2016)
- Bayer : anticoagulants (2016)
- Astra Zeneca : antiplatelet agents (2016)
- Daiichi Sankyo : antiplatelet agents (2016)
- Boehringer-Ingelheim : antithrombotics (2016)
- Janssen-Cilag : antithrombotics (2016)
- Sanofi Aventis : antithrombotics (2016)
- GlaxoSmithKline : antithrombotics (2016)
- Medicines Company : antithrombotics (2016)
- Bristol Myers Squibb : antithrombotics (2016)

23/08/2017 21/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Steg Philippe Gabriel
Studencan Martin
Sujayeva Volha
Tatu-Chitoiu Gabriel
Petrisor
Terkelsen Christian Juhl
Thygesen Kristian
Timoteo Ana Teresa
Tousek Petr
Windecker Stephan
23/08/2017
2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
Type of Relationship with Industry
- Lilly : antithrombotics and lipid lowering drugs (2016)
- Novartis : consulting (2016)
- Pfizer : Events adjudication committee (2016)
- Amarin : Lipid compounds (2016)
- CSL Behring : lipid lowering drugs (2016)
D - Research funding (departmental or institutional).
- Sanofi Aventis : Clinical trial on lipids (2016)
- Servier : Registry on coronary artery disease (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Brilique (2016)
- MSD : Esetimibe, Inegy (2016)
- Medtronic : stents (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer Ingelheim : Cardiology (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Medicine (2016)
D - Research funding (departmental or institutional).
- Terumo Inc : Coronary angiography equipment (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott Laboratories : Diagnostics (2016)
Nothing to be declared (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antiplatelet treatment (2016)
D - Research funding (departmental or institutional).
- Boston Scientific : General Cardiology (2016)
- St Jude Medical : General Cardiology (2016)
22/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Windecker Stephan - Terumo Inc : General Cardiology (2016)

- Bracco Pharmaceutical : General Cardiology (2016)
Xuereb Robert G Nothing to be declared (2016)
Yakovlev Alexey A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Acute coronary syndrome (2016)
- Boehringer-Ingelheim : Acute coronary syndrome (2016)
- Sanofi Aventis : Acute coronary syndrome (2016)
Yildirir Aylin B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis : Consultant (2016)
Zakke Ilja A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- BGP Products : Cardiology (2016)
Zamorano Gomez Jose A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
Luis - Philips : 3D Echocardiography. (2016)
- Servier : Clinical case presentation during ESC Cong 2016 (2016)
- Pfizer : speaker CV risk factors. (2016)
- MSD : speaker. CV risk factors (2016)
D - Research funding (departmental or institutional).
- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
- Abbott : Epidemiology study of Mitral regurgitation (2016)
Zeymer Uwe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antithrombotic therapy (2016)
- Boehringer-Ingelheim : Antithrombotic therapy (2016)
- Daiichi Sankyo : Antithrombotic therapy (2016)
- Eli Lilly : Antithrombotic therapy (2016)
- Sanofi Aventis : Antithrombotic therapy (2016)
- Medicines Company : Antithrombotic therapy (2016)

23/08/2017 23/33
 2017 ESC Guidelines for themanagement of acutemyocardial infarction
in patients presenting with ST-segment elevation - Reviewers
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Zeymer Uwe - Bayer AG : Antithrombotic therapy (2016)

- Pfizer : Antithrombotic therapyy (2016)
- Bristol Myers Squibb : Antithtombotic therapy (2016)
- Institut fr Herzinfarktforschung Ludwigshafen, Germany : CRO (2016)
- Medtronic : Devices (2016)
- Zoll Medical : Devices (2016)
- Novartis : Heart Failure (2016)
- Amgen : Lipid lowering therapy (2016)
- Merck Sharp & Dohme : Lipid lowering therapy, antithrombotic therapy (2016)
D - Research funding (departmental or institutional).
- Novartis : Antihypertensive therapy (2016)
- Daiichi Sankyo : antithrombotic therapy (2016)
- Bristol Myers Squibb : Antithrombotic therapy (2016)
Ztot Samir Nothing to be declared (2016)

23/08/2017 24/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Aboyans Victor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Amgen : Hyperlipidemia (2016)
- Novartis : Hypertension (2016)
- Boehringer-Ingelheim : Oral anticoagulation (2016)
- Bayer Healthcare : Oral anticoagulation (2016)
- Pfizer/BMS alliance : Oral anticoagulation (2016)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Antiplatelet treatment (2016)
Barbato Emanuele B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : Education courses on rotational atherectomy (2016)
- St Jude Medical : Educational courses on FFR (2016)
D - Research funding (departmental or institutional).
- St Jude Medical : Unrestricted grant for an investigator-driven study (2016)
Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : Apixaban (2016)
- Bristol Myers Squibb : Apixaban (2016)
- Bayer : Aspirin, rivaroxaban (2016)
- Abbott : BVS (2016)
- MEDSCAPE-the heart.og : Inespecific (2016)
- Servier : ivabradine (2016)
- Novartis : Serelaxin, ACZ885, AHF Academy (2016)
- Astra Zeneca : Ticagrelor (2016)
- Ferrer Internacional : Trinomia (polypill) (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Ticagrelor (2016)

21/08/2017 25/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Bueno Hector E - Research funding (personal).

Coca Antonio
Collet Jean-Philippe
- BMS : CV013-011 - STANDUP-AHF trial (2016)
- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)
- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016)
- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Serono : Bisoprolol-Amlodipine (2016)
- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016)
- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)
- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- BMS : apixaban (2016)
- Sanofi Aventis : CLOPIDOGREL (2016)
- Medtronic : corevalve (2016)
- Eli Lilly : PRASUGREL (2016)
- Astra-Zeneca : ticagrelor (2016)
- MSD : VORAPAXAR (2016)
- Bayer Healthcare : xarelto (2016)
D - Research funding (departmental or institutional).
- Bristol Myers Squibb : APIXABAN (2016)
- Medtronic : COREVALVE (2016)
- Stago : LABORATORY TEST (2016)
- Eli Lilly : PRASUGREL (2016)
- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

21/08/2017 26/33

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.
Expert
Collet Jean-Philippe
Coman Ioan Mircea
Delgado Victoria
21/08/2017
Committee for Practice Guidelines 2016-2018 - MEMBERS
Type of Relationship with Industry
- ICAN : THROMBOSIS (2016)
- Astra Zeneca : TICAGRELOR (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : anticoagulants (2016)
- Johnson & Johnson : antithrombotic (2016)
- Bayer AG : antithrombotic (2016)
- Sanofi Aventis : dyslipidemia (2016)
- Fournier Laboratories : dyslipidemia (2016)
- Amgen Inc : dyslipidemia , (2016)
- Novartis : HF (2016)
- Vifor International : iron deficiency (2016)
- Actelion : PHT (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : anticoagulants (2016)
- Johnson & Johnson : antithrombotic (2016)
- Bayer AG : antithrombotic (2016)
- Sanofi Aventis : dyslipidemia (2016)
- Amgen Inc : dyslipidemia (2016)
- Fournier Laboratories : dyslipidemia (2016)
- Novartis : HF (2016)
- Vifor International : iron deficiency (2016)
- Actelion : PHT (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Abbott Vascular : Mitraclip (2016)
27/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Delgado Victoria D - Research funding (departmental or institutional).

- Boston Scientific : Pacemaker-Heart failure (2016)
- Medtronic : Pacemaker-Heart failure (2016)
- Biotronik : Pacemaker-Heart Failure (2016)
- Edwards Lifesciences : Valvular heart disease (2016)
Fitzsimons Donna Nothing to be declared (2016)
Gaemperli Oliver A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- GE-Healthcare : Imaging (2016)
- Amgen Inc : PCSK9 (2016)
- Servier : Procorolan (2016)
Hindricks Gerhard B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : CIEDs and interventional electrophysiology (2016)
- St Jude Medical : CIEDs and interventional electrophysiology (2016)
- Biotronik : CIEDs and interventional electrophysiology (2016)
D - Research funding (departmental or institutional).
- Boston Scientific : CIEDs and interventional electrophysiology (2016)
- St Jude Medical : CIEDs and interventional electrophysiology (2016)
Iung Bernard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Edwards Lifesciences : Heart Valve Prostheses (2016)
Juni Peter Nothing to be declared (2016)
Katus Hugo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : Lixiana_NOAK (2016)
- Astra Zeneca : Ticagrelor (2016)
- Bayer Vital : Xarelto-NOAK (2016)
D - Research funding (departmental or institutional).
- St Jude Medical : Biobank (2016)

21/08/2017 28/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Katus Hugo - Philips : MRT (2016)

Knuuti Juhani
Lancellotti Patrizio
Leclercq Christophe
McDonagh Theresa
Piepoli Massimo Francesco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
- Orion : Brain diseases (2016)
- AC Immune : Brain diseses (2016)
- Antaros : Endocrinology (2016)
- Boehringer-Ingelheim : Neurology (2016)
- MSD : Neurology (2016)
- GE Gealthcare : Neurology (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- St Jude Medical : Echo course (2016)
- Servier : Ischemic Heart Disease (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer : NOAC (2016)
- Medtronic : Structural disease (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boston Scientific : devices (2016)
- Medtronic : devices (2016)
- Sorin Group : devices (2016)
- St Jude Medical : devices (2016)
- Biotronik : devices (2016)
- Bayer Healthcare : DOAC (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Vifor International : Ferrinject (2016)
- Novartis : Honoraria (2016)
- Servier : Committee member, Speaker fee (2016)

21/08/2017 29/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Piepoli Massimo Francesco
Ponikowski Piotr
- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)
- Amgen : Metabolic, Lipid (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis : Heart Failure Prevention Initiatives (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : anticoagulant, diabetes (2016)
- Abbott Vascular : devices (2016)
- Respicardia : devices (2016)
- BioControl : devices (2016)
- Novartis : heart failure (2016)
- Cardiorentis : heart failure (2016)
- Berlin Chemie AG : heart failure (2016)
- Bayer Healthcare : heart failure (2016)
- Vifor Pharma ltd : heart failure (2016)
- CIBIEM : heart failure (2016)
- Servier : heart failure, coronary artery disease (2016)
- Amgen : heart failure, lipids (2016)
- Pfizer : lipids (2016)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Respicardia : anticoagulant (2016)
- BioControl : devices (2016)
- DC Device : devices (2016)
- Novartis : heart failure (2016)
- Cardiorentis : heart failure (2016)

21/08/2017 30/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Ponikowski Piotr - Bayer Healthcare : heart failure (2016)

Richter Dimitrios
- CIBIEM : heart failure (2016)
- Servier : heart failure, coronary artery disease (2016)
- Amgen : heart failure, lipids (2016)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Menarini : CAD- hypertension (2016)
- Novartis : hypertension (2016)
- Abbott : lipids (2016)
- Amgen : lipids (2016)
- Sanofi Aventis : Lipids (2016)
- Lilly : Lipids (2016)
- Unilever : lipids (2016)
- Merck Sharp & Dohme : lipids (2016)
- Angelini : Lipids (2016)
- Vianex : lipids (2016)
- Galenica : Lipids (2016)
- Teva Pharmaceutical Industries : lipids, hypertension (2016)
- Swisspharma : lipids-hypertension (2016)
- Astra Zeneca : lipids-thrombosis (2016)
- Pfizer : lipids-thrombosis (2016)
- Winmedica : lipids-thrombosis (2016)
- Boehringer-Ingelheim : thrombosis (2016)
- Bayer Healthcare : Thrombosis (2016)

21/08/2017 31/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Terumo Inc : coronary catheters (2016)
- Johnson & Johnson : coronary catheters (2016)
- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)
D - Research funding (departmental or institutional).
- Boston Scientific : devices (2016)
- Medtronic : devices (2016)
- Biotronik : devices (2016)
- Terumo Inc : devices (2016)
- Abbott Vascular : devices (2016)
Shlyakhto Evgeny A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Krka Pharma : Arterial Hypertension (2016)
- Novartis : Arterial Hypertension, Heart Failure (2016)
- Merck Sharp & Dohme : Atherosclerosis (2016)
- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016)
- Pfizer : General Cardiology (2016)
Simpson Iain A Nothing to be declared (2016)
Windecker Stephan D - Research funding (departmental or institutional).
- Boston Scientific : General Cardiology (2016)
- St Jude Medical : General Cardiology (2016)
- Terumo Inc : General Cardiology (2016)
- Bracco Pharmaceutical : General Cardiology (2016)
Zamorano Gomez Jose A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
Luis - Philips : 3D Echocardiography. (2016)
- Servier : Clinical case presentation during ESC Cong 2016 (2016)

21/08/2017 32/33
 Committee for Practice Guidelines 2016-2018 - MEMBERS
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted
every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to
and including 2016.

Expert Type of Relationship with Industry

Zamorano Gomez Jose - Pfizer : speaker CV risk factors. (2016)

Luis
- MSD : speaker. CV risk factors (2016)
D - Research funding (departmental or institutional).
- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
- Abbott : Epidemiology study of Mitral regurgitation (2016)

21/08/2017 33/33